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Metformin treatment modulates the
tumour-induced wasting effects in muscle
protein metabolism minimising the
cachexia in tumour-bearing rats
André G. Oliveira and Maria Cristina C. Gomes-Marcondes*
Abstract
Background: Cancer-cachexia state frequently induces both fat and protein wasting, leading to death. In this way,
the knowledge of the mechanism of drugs and their side effects can be a new feature to treat and to have success,
contributing to a better life quality for these patients. Metformin is an oral drug used in type 2 diabetes mellitus,
showing inhibitory effect on proliferation in some neoplastic cells. For this reason, we evaluated its modulatory
effect on Walker-256 tumour evolution and also on protein metabolism in gastrocnemius muscle and body
composition.
Methods: Wistar rats received or not tumour implant and metformin treatment and were distributed into four
groups, as followed: control (C), Walker 256 tumour-bearing (W), metformin-treated (M) and tumour-bearing treated
with metformin (WM). Animals were weighed three times a week, and after cachexia state has been detected, the
rats were euthanised and muscle and tumour excised and analysed by biochemical and molecular assays.
Results: Tumour growth promoted some deleterious effects on chemical body composition, increasing water and
decreasing fat percentage, and reducing lean body mass. In muscle tissue, tumour led to a decreased protein
synthesis and an increased proteolysis, showing the higher activity of the ubiquitin-proteasome pathway. On the
other hand, the metformin treatment likely minimised the tumour-induced wasting state; in this way, this treatment
ameliorated chemical body composition, reduced the higher activities of proteolytic enzymes and decreased the
protein waste.
Conclusion: Metformin treatment not only decreases the tumour growth but also improves the protein metabolism in
gastrocnemius muscle in tumour-bearing rats.
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Background
Cancer is one of the leading causes of deaths worldwide
[1], and many cancer patients show malnutrition and
weight loss due to tumour-associated catabolic stress,
developing cancer-cachexia state. Cachexia is a complex
metabolic syndrome associated with others underlying
illness, characterised by inducing lean body mass wast-
ing, with or without fat mass loss [2]. Depending on the
type of cancer, more than 50 % of cancer patients
present cachexia, and this is one of the most frequent
cause of morbidity and mortality [3]. In cancer cachexia,
the major pathway responsible for muscle protein deg-
radation is the ubiquitin-proteasome pathway (UPP) [4]
which consists of a set of enzymes that couples target
proteins to ubiquitin molecules, which are degraded by
the 26S proteasome [5]. In tumour cells, the phosphoi-
nositide 3-kinase (PI3K)–Akt–mammalian target of
rapamycin (mTOR) pathway is always turned on due to
mutation of key genes in this pathway. On the other
hand, in muscle cells, this pathway is responsible mainly
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for control protein synthesis and degradation process
[6]. Akt activation by insulin has been linked to suppres-
sion of FOXO (forkhead box O) and caspase-3 activity
and also to a decrease in ubiquitin ligases expression [7].
In this way, many cancer patients experience insulin
resistance in some extend, which in certain cases lead to
an increased protein degradation by FOXO and higher
UPP activity [7].
AMP-activated protein kinase (AMPK) plays an essen-
tial role maintaining the cellular energetic status, acting
as a fuel gauge. This process helps cells to deal with
energy stress conditions and bring them back to hom-
oeostasis [8], controlling processes such as protein
synthesis. Metformin (1,1-dimethylbiguanide) is an oral
drug widely used in type 2 diabetes mellitus (T2DM)
treatment, being prescribed to more than 120 million of
people worldwide [8] and many studies shows that
T2DM patients treated with metformin have a lower risk
of developing cancer [9, 10]. The mechanism by which
metformin act is not completely understood, but it
seems to be through phosphorylation and activation of
AMPK. However, this effect on AMPK activation is in-
direct and might be an inhibitory effect on mitochon-
drial respiratory chain complex 1 [11–13].
Despite the fact that metformin can decrease insulin
levels and tumour’s cell proliferation [14], few studies
analyse metformin action on skeletal muscle in cachexia
models. Therefore, here we hypothesise that metformin
could decrease the inhibitory effect on insulin signalling
in muscle tissue caused by tumour growth.
Methods
Animals and tumour implant
Male Wistar rats weighted within 60–70 g (3 weeks old)
were obtained from the animal facility CEMIB/State
University of Campinas and housed in a collective cage,
maintained at 22 ± 2 °C and 12 h light/dark cycles. Ani-
mals were allowed to a normoprotein semi-purified diet
(18 % of protein source, following the AIN-93G recom-
mendations) [15] and water ad libitum. Walker 256 cells
were originally obtained from Christ Hospital (USA) and
maintained in our laboratory through consecutive
intraperitoneal passages; 1 × 106 viable tumour cells, in
0.2 mL NaCl suspension, were implanted subcutaneously
in the right flank, while the rats without tumour re-
ceived 0.2 mL of 0.9 % NaCl injection as a sham proced-
ure. The general UKCCCR [16, 17] guidelines were
followed, and the experimental protocol (#895-1) was
approved by the Ethical Committee of the State Uni-
versity of Campinas.
Metformin treatment and experimental procedures
Metformin was dissolved in drinking water (100 mg/L)
which corresponded to 33 mg/Kg body weight.
Metformin concentration was estimated using the allo-
metric scaling [18, 19] from human data, using the initial
recommended dose for T2DM patients (500 mg/day).
Animals were distributed into four groups: control (C),
Walker 256 tumour-bearing (W), metformin-treated (M)
and tumour-bearing treated with metformin (WM).
Tumour weight was measured as previously described
[20] and when tumour mass in W animals reached 10 %
of body mass, the animals were subjected to overnight
fast time (12 h) and euthanatized by cervical dislocation.
A blood sample was collected by cardiac puncture.
Carcass weight was obtained by weighing the animals
without gastrointestinal tract and tumour mass. Both
gastrocnemius muscle and tumour tissue were expressed
as the percentage of the carcass weight.
Biochemical body composition assay was previously
described [21]. The samples of dried and fat-extracted
carcasses were analysed for total nitrogen spectrophoto-
metrically [22]. Another sample was submitted to
alkaline digestion for collagen nitrogen determination
[22]. Non-collagen nitrogen was calculated by subtract-
ing collagen nitrogen from total nitrogen.
Serum proteins concentration
Total serum proteins and albumin were quantified spec-
trophotometrically [23] (Laborlab, Brazil), and the differ-
ence between total serum protein and albumin contents
we calculated the serum globulin content.
Gastrocnemius muscle sampling and enzymatic assays
Immediately after euthanasia, the gastrocnemius muscles
were dissected, frozen in liquid nitrogen and kept at -
80 °C. A sample was then homogenised in phosphate
buffer saline (PBS) (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4), pH 7.4, 0.1 %
Triton X-100 and the supernatant was used for protein
concentration [24] and all enzymatic activity assays.
Calpain [25], cathepsin B and H [26] and chymotrypsin
activity [27] were assayed as previously described without
modification.
Muscle protein degradation and synthesis
Right gastrocnemius muscle was dissected and incubated
with 0.5 μCi/mL L-[2,3,4,5,6-3H] phenylalanine (Amer-
sham, UK) for protein synthesis assay while left muscle
was incubated with 0.5 mM cycloheximide for protein
degradation assay. Radioactive phenylalanine incorpo-
rated into muscle and tyrosine released in incubation
buffer were assayed as described [28]. Protein turnover
was defined as the ratio of protein synthesis and protein
degradation.
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Immunoblotting
Immunoblotting was performed as previously described
[20]. Proteins were probed with primary antibodies
GAPDH (sc-25778), Ubiquitin (sc-6085), UBE2A/B (sc-
10479) (Santa Cruz Biotechnology, USA); 20S (PW8195),
19S (PW8165), 11S (PW8185) (Enzo-Biomol, USA);
AMPK (2603), phospho-AMPKαThr172 (2535), Akt (4685),
phospho-AktThr308 (4056), goat anti-rabbit (7074), horse
anti-mouse (7076) (Cell Signalling, USA) and rabbit anti-
goat (AP106P) (MerckMillipore, USA). Images were cap-
tured using Alliance 2.7 (UVItec, UK) and band intensity
was quantified using UVIband -1D (UVItec, UK).
Statistical analysis
The nonparametric t-test was used for comparison be-
tween two groups. Comparison among groups, we used
One-way ANOVA followed by Bonferroni post-test,
using GraphPad Prism version 5.00 software (GraphPad,
USA) and results showed as mean ± standard deviation
(SD). Significance was defined as p < 0.05.
Results
Metformin treatment attenuates effects of tumour growth
on body composition
To analyse whether tumour growth led to cachexia and
whether metformin treatment, at close therapeutic dose
used in T2DM patients, was able to reduce the tumour
harmfull effect, we analysed the biochemical body
composition parameters. As can be seen in Table 1, W
animals developed cachexia. Although final body weight
decreased in both tumour-bearing groups, the W group
weight was approximately 10 % less than C rats, while
the WM group had no difference compared to C. Body
water content increased in both tumour-bearing groups;
in the opposite way, the body fat reduced in W and WM
groups. Lean body mass in W group was around 89 % of
C group while the WM had similar value compared to
C. Comparing both tumour-bearing groups, the results
showed that WM had approximately 8 % lean body mass
higher than W. In addition, carcass protein reduced in
W (15 % lower) and WM (12 % less) in comparison to
control group. The carcass collagen nitrogen also re-
duced by tumour effects, being 35 % lower in W group,
while decreased around 13 % in WM group; this result
showed that metformin treatment led to maintenance of
collagen nitrogen in WM when compared to W group.
The decrease in gastrocnemius weight happened in both
tumour-bearing groups, being 22 % less in W and only
14 % in WM; comparing both tumour-bearing groups,
in WM the muscle mass was 10 % higher than in W
group. The muscle protein content reduced approxi-
mately 15 % in W, whereas WM group was similar to C.
Tumour weight was not different between W and WM,
although the relative tumour weight was around 23 %
less in WM compared to W.
Total serum protein decreased by 15 % in W com-
pared to C, whereas WM had similar content as C rats,
and increased 11 % when compared to W. Albumin
Table 1 Tumour growth effects on body composition, tissues weight rate and serum cachexia markers
C (n = 12) W (n = 12) M (n = 12) WM (n = 12)
Initial body weight (g) 65.8 ± 13.4 67.1 ± 11.3 67.2 ± 14.1 67.9 ± 11.2
Final body weight (g) 131.5 ± 14.3 119.5 ± 11.6* 135.2 ± 14.1 123.2 ± 11.5
Body water (%) 69.1 ± 1.8 73.6 ± 2.1*** 69.1 ± 1.0 72.9 ± 2.7***
Body fat (%) 5.6 ± 1.9 2.9 ± 1.3*** 6.3 ± 0.9 3.4 ± 1.6**
Lean body mass (%) 24.0 ± 2.9 21.3 ± 3.2* 23.5 ± 3.3 23.0 ± 3.4
Carcass protein (mg/g) 30.9 ± 1.8 26.4 ± 2.1*** 30.9 ± 1.0 27.1 ± 2.7***
Collagen nitrogen (mg/100 g) 21.7 ± 5.6 14.2 ± 5.9** 19.2 ± 6.7 18.8 ± 4.8#
Non-collagen nitrogen (mg/100 g) 83.5 ± 7.2 88.4 ± 6.4 87.5 ± 6.2 84.8 ± 3.7
Total nitrogen (mg/100 g) 105.2 ± 7.1 100.1 ± 5.7 100.7 ± 11.0 103.3 ± 5.1
Muscle relative weight (%) 0.62 ± 0.05 0.48 ± 0.08*** 0.62 ± 0.05 0.53 ± 0.07***
Muscular protein (μg/μL) 5.3 ± 0.2 4.5 ± 0.1* 5.5 ± 0.3 5.0 ± 0.2#
Tumour weight (g) - 11.4 ± 3.1 - 10.1 ± 3.3
Tumour relative weight (g) - 14.1 ± 4.0 - 10.9 ± 2.8#
Total plasma protein (g/dL) 5.4 ± 0.3 4.6 ± 0.4* 5.7 ± 0.9 5.0 ± 0.5#
Albumin (g/dL) 3.0 ± 0.1 2.3 ± 0.2*** 2.9 ± 0.1 2.3 ± 0.3***
Globulin (g/dL) 3.2 ± 0.5 2.4 ± 0.3* 3.1 ± 0.9 2.6 ± 0.3
Legend: C, control rats; W, Walker 256 tumour-bearing rats; M, metformin-treated rats (33 mg/Kg); WM, Walker 256 tumour-bearing rats treated with metformin
(33 mg/Kg). Number of animals per group = 12. Data are presented as mean ± SD. *p < 0.05 vs C; **p < 0.01 vs C; ***p < 0.001 vs C; #p < 0.05 vs W; ##p < 0.01 vs W
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content reduced around 23 % in each W and WM
group, while globulin concentration decreased only in
W (22 % lower) (Table 1).
Metformin decreases the tumour–induced protein
degradation and ameliorates the protein turnover
Once many body parameters (Table 1) showed that
tumour-bearing animals were cachectic, one might
expect that protein synthesis was impaired associated to
an increased protein degradation. To address this ques-
tion, we analysed both protein synthesis and degrad-
ation. The tumour led to a decrease in gastrocnemius
muscle protein synthesis, being 90 % less in W and 60 %
in WM group when compared to C group (Fig. 1a). In
parallel, tumour growth induced a significant increase in
protein degradation in W group (90 % higher) and also
in WM group (74 %; Fig. 1b). Despite having a tumour,
the metformin treatment (WM group) induced a lower
reduction in protein synthesis associated with a non-
altered protein degradation (p = 0.0571). In this way, the
ratio of muscle protein synthesis and degradation was
deeply reduced in W (93 % less) whereas in WM this ef-
fect was modulated by metformin, being 4-times higher
in WM than in W group (Fig. 1c).
Proteasome is the major pathway for protein degradation
in gastrocnemius muscle of tumour-bearing animals
To address which protein degradation pathway was
affecting the muscle mass and protein content in gastro-
cnemius, we analysed the three major protein degrad-
ation pathways. The calpain, cathepsin B and cathepsin
H activities were similar in all experimental groups
(Fig. 2a-c). Chymotrypsin-like activity was 64 % higher
in W, while in WM this enzyme activity was similar to
C (Fig. 2d). The comparison between tumour-bearing
groups showed that metformin treatment modulated the
chymotrypsin-like activity by 38 % less compared to
non-treated group (Fig. 2d).
Metformin minimises the effects of tumour growth in
both synthesis and degradation pathways in
gastrocnemius muscle
Metformin treatment greatly influenced the expression
of proteins responsible for coordinating both synthesis
and degradation processes in muscle. The ratio p-
AMPK/AMPK increased two-fold in W while the WM
showed similar value to C. The comparison between
both tumour-bearing groups indicated that the effect of
metformin treatment was remarkable; WM had 61 %
lower p-AMPK/AMPK expression than W (Fig. 3a and b).
The ratio of p-Akt/Akt was decreased approximately 63 %
in W and was not affected in WM. On the other hand, the
Akt activation in WM increased around 118 % compared
to W (Fig. 3a and c).
Both proteasome 20S subunits (32 and 28 KDa) expres-
sion increased in W but not in WM (Fig. 4a, b and c). The
32 KDa subunit enhanced approximately by 52 % in W
while in WM had no change compared to C. When
Fig. 1 Metformin increases protein turnover in gastrocnemius
muscle of Walker 256 tumour-bearing rats. a Right gastrocnemius
muscle was pre-incubated for 30 min at 37 °C, in KHB buffer. Then,
muscle was incubated for 2 h at 37 °C in KHB containing 0.5 μCi/
mL L-[2,3,4,5,6-3H] Phenylalanine. Phenylalanine incorporated into
muscle proteins represents protein synthesis rate. b Left gastrocnemius
muscle was preincubated for 30 min at 37 °C in KHB buffer; then,
additional incubation (2 h at 37 °C) in KHB containing 0.5 mM
cycloheximyde; tyrosine released in incubation medium represents
protein degradation rate. c Ratio between incorporated phenylalanine
and released tyrosine was defined as protein turnover rate. Legend: C,
control rats; W, Walker 256 tumour-bearing rats; M, metformin-treated
rats (33 mg/Kg); WM, Walker 256 tumour-bearing rats treated with
metformin (33 mg/Kg). Number of animals per group = 6. Columns
represent mean ± SD. *p < 0.05 vs C; **p < 0.01 vs C; ##p < 0.01 vs W
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compared to W, the expression of the 32 KDa subunit
reduced around 36 % in WM (Fig. 4a and b). The 28
KDa subunit increased by 20 % in W and had no
change in WM. Comparing both tumour-bearing
groups, the expression of the 28 KDa subunit decreased
approximately 22 % in WM (Fig. 4a and c). The 19S
subunit expression increased around 57 % only in W
group, while the WM had similar value compared to C
(Fig. 4a and d). The 11S subunit expression increased
approximately 31 % in W but had no change in WM
(Fig. 4a and e). The UBE2A/B expression enhanced
around 90 % in W compared to C whereas the WM
group had no change (Fig. 4a and f ). The ubiquitin
expression was not affected either by the tumour or
metformin treatment (Fig. 4a and g).
Discussion
Cachexia is a common feature of many cancers, being
responsible to worse prognosis in patients with different
types of cancers [29], and is characterised as an involun-
tary weight loss, reduction of body fat and mainly the
lean body mass [2]. We verified that metformin at a
similar concentration to that prescribed to T2DM pa-
tients was able to minimise lean body mass loss and pre-
served protein content in gastrocnemius muscle. Many
studies have shown that metformin can reduce cell
proliferation in different tumour cell types [30, 31] and
the results showed here are not exclusively due to a
reduced tumour mass in metformin-treated animals.
Some tumours release factors that can change host
metabolism and induce weight loss, mainly the lean
body mass [32]. Besides lean body mass waste, tumour-
bearing animals also showed a significant change in
other parameters that indicates the establishment of the
cachectic state, such as fat mass, water content and
serum albumin concentration. Metformin treatment was
able to ameliorate some of these effects possibly not de-
creasing any factor released by tumour but diminishing
the impact of those factors on the host cells.
Tumour cells have an increased metabolic rate
compared to non-tumour cells, probably because of the
highly proliferative cell activity, which depends on a
good provision of nutrients mobilised from host tissues.
Due to that, metabolic tumour reprogramming has been
described as a new cancer hallmark [33] and the possi-
bility to explore these alterations using metformin treat-
ment seems an excellent therapeutic opportunity. The
ATP generation by aerobic glycolysis, which was de-
scribed as the Warburg effect [34], is an efficient way by
which tumour cells can get energy. On the other hand,
these cells also need carbon and nitrogen source
provided from other via such as tricarboxylic acid
Fig. 2 Muscle proteins are mainly degraded by proteasome pathway in Walker 256 tumour-bearing rats and metformin modulates this via.
Enzyme activity of three different protein degradation pathways was analysed: (a) calcium-dependent pathway, (b and c) lysosomal pathway and
(d) ubiquitin-proteasome pathway. Metformin modulates chymotrypsin-like activity in Walker 256 tumour-bearing rats bring the value close to C.
Legend: C, control rats; W, Walker 256 tumour-bearing rats; M, metformin-treated rats (33 mg/Kg); WM, Walker 256 tumour-bearing rats treated
with metformin (33 mg/Kg). Number of animals per group = 8. Columns represent mean ± SD. *p < 0.05 vs C; #p < 0.05 vs W
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(TCA) cycle [35], whereas, parallel to the source of en-
ergy to tumour cells, the respiratory chain is still neces-
sary to supply the biosynthetic pathways with precursor
molecules such as lactate and alanine. The energy neces-
sary to such neoplastic cells activities derives mainly
from aerobic glycolysis, the increased rate of biosyn-
thetic precursors and the maintenance of redox state are
the most important needs of highly proliferative cells
[36]. We have shown in our previous work that Walker
256 tumour-bearing animals have an increased lactate
production while the metformin-treated tumour-bearing
animals had a reduction of serum lactate concentration
[20]. The lactate produced by tumour metabolism is
carried to the liver and then converted back to glucose
Fig. 3 Metformin decreases inhibitory effects on protein synthesis in gastrocnemius muscle caused by tumour growth. Two different mTOR
upstream proteins were analyzed by immunoblotting. a Representative image from at least four independent experiments. b AMPK was activated
in W but not in WM, as showed by p-AMPK expression. c Akt phosphorylation was inhibited in untreated tumour-bearing animal (W) while in
metformin-treated animals the activation was similar to control groups. Graphs (b) and (c) represent bands quantified and normalised by GAPDH
expression. Values are relative percentage of C group, referred as 100 %. Legend: C, control rats; W, Walker 256 tumour-bearing rats; M,
metformin-treated rats (33 mg/Kg); WM, Walker 256 tumour-bearing rats treated with metformin (33 mg/Kg). Columns represent mean ± SD.
**p < 0.01 vs C; ***p < 0.001 vs C; #p < 0.05 vs W; ###p < 0.001 vs W
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by gluconeogenesis, consuming three ATP molecules to
generate glucose for each lactate molecule. In the same
fashion, when muscle proteolysis occurs the generated
alanine is transported by the bloodstream to the liver,
where is converted to glucose. This reaction known as
Cori Cycle could account for an additional loss of energy
in cancer patients being at least 300 Kcal/day [37].
Animals bearing Walker 256 tumour have a reduced
insulin secretion [38]. A decreased insulin-to-glucagon
ratio indicates a starvation-like condition and, for this
reason, the host cells or tissues are not able to prevent
protein degradation, occurring lean body mass loss. We
demonstrated that tumour growth led to a decrease in
protein synthesis and increased protein degradation,
Fig. 4 Expression of proteins of ubiquitin-proteasome pathway are increased in Walker 256 tumour-bearing rats and metformin is able to restore
similar levels as C group. a Representative image from at least four independent experiments. Expression of proteasome 20S subunit, the 32 KDa
subunit (b) and the 28 KDa subunit (c) were analyzed by immunoblotting. Regulatory proteasome subunits 19S (d) and 11S (e) likewise the
ubiquitin-conjugating enzyme E2 (f) and ubiquitin itself (g) were also analysed by immunoblotting. Graphs from (b) to (g) represent bands
quantified and normalised by GAPDH expression. Values are expressed as relative percentage of C group, referred as 100 %. Legend: C, control
rats; W, Walker 256 tumour-bearing rats; M, metformin-treated rats (33 mg/Kg); WM, Walker 256 tumour-bearing rats treated with metformin
(33 mg/Kg). Columns represent mean ± SD. *p < 0.05 vs C; #p < 0.05 vs W
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reducing the gastrocnemius relative weight associated
with a low muscle protein concentration as well as the
lean body mass. The net protein loss in gastrocnemius
muscle is likely due to a decreased Akt activation and an
increased AMPK activation. Akt is phosphorylated and
activated in a pathway triggered by insulin, which con-
trols processes such as cell growth, metabolism, prolifer-
ation, glucose uptake, survival and angiogenesis [39].
Reduced circulating insulin means a reduction in Akt
activation, leading to inhibition of mTORC1; whereas
the phosphorylation by Akt, mTORC1 is activated, lead-
ing to protein synthesis process [40]. Conversely, AMPK
is activated when the AMP:ATP ratio is high and in-
hibits mTOR, preventing additional energy expenditure.
Tumour growth promotes lean mass spoliation in a
manner to obtain substrates to keep growing and sustain
the tumour cells high metabolic demands. In this sense,
metformin treatment was efficient in minimising the
protein depletion in gastrocnemius muscle.
We demonstrated that cytosolic degradation pathways,
including calpain and cathepsin, were not activated in
muscle of Walker 256 tumour-bearing animals, but the
UPP is the main pathway by which muscle protein were
degraded in these animals. The UPP handles muscle
protein degradation in both human [41] and mouse [42]
that have a tumour. In our previous work, it was demon-
strated that Walker 256 tumour releases a cachectic
factor similar to proteolysis-inducing factor (PIF) [43]
and this factor was able to induce protein degradation
and inhibit protein synthesis in myotubes cultured [43].
Although the PIF-like expression was not analysed in
this work, probably the metformin led to a modulatory
effect minimising the harmful effects over gastrocnemius
tissue. PIF induces muscle cells to enhance UPP proteins
expression and hence increasing protein degradation. A
recent review pointed out the importance of ubiquitin
ligases in the protein degradation process and how Akt
activation stimulated by insulin was able to modulate it
[7]. In our work, we have demonstrated that metformin
treatment in tumour-bearing animals was able to keep
UPP protein levels similar to the control group and,
therefore, decreasing tumour effects in skeletal muscle.
It is possible that metformin could maintain the insulin
level close to the control group values; in our previous
finds, we verified maintenance of insulin content in
tumour-bearing rats treated with higher metformin dose.
In this way, insulin activates Akt and, therefore, phos-
phorylate FoxO3a keeping it in the cytosol, inhibiting to
act as a transcription factor for ubiquitin-ligases.
Overall, metformin treatment was able to decrease
tumour growth (as the tumour/body weight ratio) and
also able to decrease the harmful tumour effects on
protein metabolism in skeletal muscle. As previously
stated, metformin treatment is also known to inhibit
mitochondrial complex I and, therefore, may be impli-
cated in decreasing TCA intermediates [44]. In this sce-
nario, as a probable mechanism of action, the metformin
can be a toll on cancer treatment by decreasing the flux
of molecules to biosynthetic pathways and the gener-
ation of reactive oxygen species (ROS) on tumour cells.
However, ROS act as a double-edged sword in cancer
progression; within certain limits, it can act as a growth-
promoting agent, but in this case under metformin treat-
ment, maybe there was a direct action to cell death [45].
It demonstrates the complexity of using the metabolic
approach against tumour growth due to its high plasti-
city and heterogeneity [46].
Despite the fact that action mechanism of metformin
is not completely understood, using it in laboratory ani-
mal models has shown remarkable antineoplastic effects
[47]. However, further molecular data are needed to
clarify this question, increasing the chance to use to use
metformin as a therapeutic drug, because the evidences
that metformin can be used as an adjuvant in cancer
treatment are still incipient and its applicability needs to
be confirmed in clinical trials.
Conclusion
Taking all data together, we conclude that the cachectic
state developed by tumour effects, mainly impairing the
muscle tissue, as a consequence of higher activity of the
ubiquitin-proteasome pathway, can be minimised under
metformin treatment as this treatment ameliorated
chemical body composition, reducing the ubiquitin-
proteasome pathway, which decreased the protein waste.
In summary, metformin remains a promising tool in
cancer studies and how it could attenuate cachexia in
tumour-bearing animals is a subject for further research.
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